Aqr Capital Management LLC Aerie Pharmaceuticals Inc Transaction History

Aqr Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.37 - $15.23 $321,194 - $767,942	-50,423 Reduced 62.24%	30,590 $463,000
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $206,974 - $383,007	41,813 Added 106.67%	81,013 $608,000
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $81,892 - $142,296	14,520 Added 58.83%	39,200 $357,000
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $143,938 - $273,318	20,504 Added 491.0%	24,680 $173,000
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $341,696 - $503,083	-7,141 Reduced 63.1%	4,176 $282,000
Q1 2018 May 15, 2018	SELL	$51.15 - $61.0 $515,285 - $614,514	-10,074 Reduced 47.09%	11,317 $614,000
Q4 2017 Feb 14, 2018	SELL	$50.85 - $65.1 $695,983 - $891,023	-13,687 Reduced 39.02%	21,391 $1.28 Million
Q3 2017 Nov 14, 2017	BUY	$48.6 - $60.1 $1.7 Million - $2.11 Million	35,078	35,078 $1.71 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.